Cetrorelix CAS No: 120287-85-6 Cetrorelix is traditionally used as fertility API that binds to a hormone receptor to stop gonadotropin secretion. While it may be associated with women undergoing ovarian stimulation, it appears as though there’s more to this API that meets the eye. This synthetic decapeptide is being studied to help with a variety of conditions, including the[…]
Cetrorelix: A Fertility Drug that Shows Promise to Treat Pregnant Women with PCOS in the Future
Hormonal Agent, Synthetic Peptide Tags: PCOSPolycystic Ovarian SyndromePregnancy Dec 12, 2018
Octreotide Acetate: Managing Growth-Release Hormones to Reduce Symptoms and Promote Balance
Hormonal Agent Tags: acromegalygrowth hormone Aug 27, 2018
Octreotide Acetate CAS #: 79517-01-04 Octreotide Acetate is prescribed for a variety of GI issues, mainly for severe diarrhea brought upon by carcinoid symptoms. Its designed to imitate the natural growth-hormone inhibitor in the body, which makes it easier for the endocrine system to do its job. This API limits the excess release of glucagon secretion and insulin, making[…]
Fluocinolone Acetonide Approved for Diabetic Macular Edema
Anti-Inflammatory, Hormonal Agent, OTC and Compounding Product Tags: Europe Jul 17, 2014
As the leading cause of blindness in the United States Diabetic Macular Edema {DME} is a serious concern for the growing aging population, affecting roughly one million Americans. The recent announcement from pSivida Corp. regarding the marketing authorization in the EU of their DME treatment Fluocinolone is hopeful for U.S. supporters of this formidable drug.[…]
Pasireotide is a Powerful Opponent Against Acromegaly
Drug Research & Development API, Hormonal Agent May 12, 2014
As a hormonal disorder caused by the pituitary gland producing an excess of the growth hormone during adulthood, acromegaly typically affects middle aged adults. Occasionally this challenging disorder affects children as well, in the form of gigantism. The changes which occur in adults with acromegaly tend to be slow growing, leading many patients to be[…]
Calcitriol Poised for FDA Approval as Vitamin D to Treat Hypocalcemia
Hormonal Agent, Hypocalcemia, Patent Expiration 2019 Tags: hypocalcemia Feb 10, 2014
The biopharmaceutical company Rockwell Medical is anxiously awaiting approval from the FDA for its injectable Vitamin D drug, Calcitriol CAS# 32222-06-3. This promising new indication approval was submitted in April of 2013, with the goal of better managing hypocalcemia in patients who experience chronic renal dialysis. As an active injectable treatment known as the brand[…]
FDA Recommends Approval of Sleep Disorder Drug Tasimelteon
Drug Research & Development API, Hormonal Agent Dec 04, 2013
In mid-November 2013 the FDA announced their recommendation for the approval of Tasimelteon for the treatment of non-24-disorder. This rare condition, which primarily affects the blind, occurs when the body’s biological clock does not work properly. Patients who are blind and experience this frustrating type of insomnia can now find relief, as Tasimelteon effectively resets[…]
Eplerenone for Acute ST-Segment Elevation Myocardial Infarction
Drug Research & Development API, Hormonal Agent, Patent Expiration 2019 Tags: congestive heart failurehypertensionPfizer Nov 13, 2013
Exciting results were revealed in Mid-March of 2013 when the REMINDER trial touted the success of Eplerenone for treating acute ST-Segment Elevation Myocardial Infarction, also known as STEMI. The results from this study were presented at the 62nd Annual Scientific Session of the American College of Cardiology, by Pfizer, who markets Inspra which is the[…]
Ethinyl Estradiol and Norgestimate 2012 U.S. Sales Exceed $425 Million
Hormonal Agent, OTC and Compounding Product, Patent Expiration 2019 Nov 12, 2013
Ethinyl Estradiol CAS# 57-63-6 Ethinyl Estradiol, CAS number 57-63-6 and Norgestimate, CAS number 35189-28-7, are both integral components in the blockbuster birth control pill Ortho Tri-Cyclen Lo. Mylan and Janssen, who market Ortho Tri-Cyclen Lo, reported an astounding 425.5 million dollars in sales for the United States for the 2012 year. With the patent for[…]
Testosterone Therapy Leads to Decreased Pain Perception in Men
Hormonal Agent, OTC and Compounding Product, Patent Expiration 2019 Nov 04, 2013
Testosterone CAS# 58-22-0, made the pharmaceutical headlines mid June 2013 when study findings were announced touting testosterone for perceived pain relief. Data presented on June 17, 2013, at the Endocrine Society’s 95th Annual Meeting offered positive results regarding the use of testosterone to improve pain tolerance. The study funded by Abbott Pharmaceuticals, involved 84 men who[…]
FDA Approves Bazedoxifene and Conjugated Estrogens to Treat Hot Flashes and Prevent Osteoporosis
Drug Research & Development API, Hormonal Agent, Osteoporosis Tags: osteoporosis Oct 16, 2013
On October 3, 2013 the FDA approved the new medication Duavee, comprised of Bazedoxifene and conjugated estrogens (Premarin) to treat hot flashes in postmenopausal women. The unique ability of this novel treatment to curtail hot flashes and help prevent osteoporosis is encouraging for gynecologists and their female patients who are experiencing post-menopause. The combination of[…]
- 1
- 2
